RxDoctor Payments DataLook up a doctor →

Nishant Gupta, MD

Pulmonary Disease · Cincinnati, OHNPI 1487848875

Payments from drug & device makers

$1,544,102in general payments, 2019–2025

Across 343 payments — averaging $4501.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$524K
  • E.r. Squibb & Sons, L.L.C.$368K
  • Boehringer Ingelheim$342K
  • Roche Products Limited$115K
  • CSL Behring$80K
  • Pfizer$48K
  • plus $67K from 9 others

What the payments were for

  • Consulting fees$11,50084%
  • Speaking & faculty fees$6165%
  • Travel & lodging$1,1759%
  • Food & beverage$3322%
  • Education$30%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,544,102 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$13,776
Medicare patients
90
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate39$416,769
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$15,286
Mycophenolate Mofetil57$13,967
Sirolimus21$10,730
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$10,300
Spiriva RespimatTiotropium Bromide16$8,492
SymbicortBudesonide/Formoterol Fumarate13$4,935
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$3,051
Hydroxychloroquine Sulfate34$2,553
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,291
Azathioprine17$2,045
Albuterol Sulfate HfaAlbuterol Sulfate64$1,550
MethotrexateMethotrexate Sodium45$1,304
Prednisone144$1,175
Azithromycin28$751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$342,201$425,26155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →